Enhanced combination therapy effect on paclitaxel-resistant carcinoma by chloroquine co-delivery via liposomes

Menghua Gao,1 Yuzhen Xu,1 Liyan Qiu2,3 1College of Pharmaceutical Sciences, 2Ministry of Education (MOE) Key Laboratory of Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 3Collaborative Innovation Center for Biotherapy, West Ch...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gao MH, Xu YZ, Qiu LY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/1108ed79afc94d2eb9442567819c29fe
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1108ed79afc94d2eb9442567819c29fe
record_format	dspace
spelling	oai:doaj.org-article:1108ed79afc94d2eb9442567819c29fe2021-12-02T00:06:57ZEnhanced combination therapy effect on paclitaxel-resistant carcinoma by chloroquine co-delivery via liposomes1178-2013https://doaj.org/article/1108ed79afc94d2eb9442567819c29fe2015-10-01T00:00:00Zhttps://www.dovepress.com/enhanced-combination-therapy-effect-on-paclitaxel-resistant-carcinoma--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Menghua Gao,1 Yuzhen Xu,1 Liyan Qiu2,3 1College of Pharmaceutical Sciences, 2Ministry of Education (MOE) Key Laboratory of Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 3Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, People’s Republic of China Abstract: A novel composite liposomal system co-encapsulating paclitaxel (PTX) with chloroquine phosphate (CQ) was designed for treating PTX-resistant carcinoma. It was confirmed that liposomal CQ can sensitize PTX by means of autophagy inhibition and competitively binding with multidrug-resistance transporters. Furthermore, according to the in vitro cytotoxicity and apoptosis assay, real-time observation of cellular uptake, and in vivo tissue distribution study, co-encapsulation of PTX and CQ in liposomes was validated as superior to the mixture of PTX liposome plus CQ liposome due to the simultaneous delivery and synergetic effect of the two drugs. Consequently, this composite liposome achieved significantly stronger anticancer efficacy in vivo than the PTX liposome plus CQ liposome mixture. This study helps to guide and enlighten ongoing and future clinical trials about the optimal administration modes for drug combination therapy. Keywords: paclitaxel, chloroquine, liposome, drug resistance, combination therapyGao MHXu YZQiu LYDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2015, Iss default, Pp 6615-6632 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Gao MH Xu YZ Qiu LY Enhanced combination therapy effect on paclitaxel-resistant carcinoma by chloroquine co-delivery via liposomes
description	Menghua Gao,1 Yuzhen Xu,1 Liyan Qiu2,3 1College of Pharmaceutical Sciences, 2Ministry of Education (MOE) Key Laboratory of Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 3Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, People’s Republic of China Abstract: A novel composite liposomal system co-encapsulating paclitaxel (PTX) with chloroquine phosphate (CQ) was designed for treating PTX-resistant carcinoma. It was confirmed that liposomal CQ can sensitize PTX by means of autophagy inhibition and competitively binding with multidrug-resistance transporters. Furthermore, according to the in vitro cytotoxicity and apoptosis assay, real-time observation of cellular uptake, and in vivo tissue distribution study, co-encapsulation of PTX and CQ in liposomes was validated as superior to the mixture of PTX liposome plus CQ liposome due to the simultaneous delivery and synergetic effect of the two drugs. Consequently, this composite liposome achieved significantly stronger anticancer efficacy in vivo than the PTX liposome plus CQ liposome mixture. This study helps to guide and enlighten ongoing and future clinical trials about the optimal administration modes for drug combination therapy. Keywords: paclitaxel, chloroquine, liposome, drug resistance, combination therapy
format	article
author	Gao MH Xu YZ Qiu LY
author_facet	Gao MH Xu YZ Qiu LY
author_sort	Gao MH
title	Enhanced combination therapy effect on paclitaxel-resistant carcinoma by chloroquine co-delivery via liposomes
title_short	Enhanced combination therapy effect on paclitaxel-resistant carcinoma by chloroquine co-delivery via liposomes
title_full	Enhanced combination therapy effect on paclitaxel-resistant carcinoma by chloroquine co-delivery via liposomes
title_fullStr	Enhanced combination therapy effect on paclitaxel-resistant carcinoma by chloroquine co-delivery via liposomes
title_full_unstemmed	Enhanced combination therapy effect on paclitaxel-resistant carcinoma by chloroquine co-delivery via liposomes
title_sort	enhanced combination therapy effect on paclitaxel-resistant carcinoma by chloroquine co-delivery via liposomes
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/1108ed79afc94d2eb9442567819c29fe
work_keys_str_mv	AT gaomh enhancedcombinationtherapyeffectonpaclitaxelresistantcarcinomabychloroquinecodeliveryvialiposomes AT xuyz enhancedcombinationtherapyeffectonpaclitaxelresistantcarcinomabychloroquinecodeliveryvialiposomes AT qiuly enhancedcombinationtherapyeffectonpaclitaxelresistantcarcinomabychloroquinecodeliveryvialiposomes
_version_	1718403909161058304

Enhanced combination therapy effect on paclitaxel-resistant carcinoma by chloroquine co-delivery via liposomes

Ejemplares similares